Evidence map›Paper›PMID 40208387›Full record

ReviewBiogerontology2025

Fisetin: hormesis accounts for many of its chemoprotective effects.

Edward J Calabrese, Peter Pressman, A Wallace Hayes, Evgenios Agathokleous, Gaurav Dhawan, Rachna Kapoor, Japjee Parmar, Ibrahim Mssillou, Vittorio Calabrese

Abstract readReview
PubMed Publisher
In one paragraph

Review in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edward J CalabreseDepartment of Environmental Health, School of Public Health and Health Sciences, University of Massachusetts, Morrill I-N344, Amherst, MA, 01003, USA. edwardc@umass.edu.
Peter PressmanUniversity of Maine, 5728 Fernald Hall, Room 201, Orono, ME, 04469, USA.
A Wallace HayesCenter for Environmental Occupational Risk Analysis and Management, College of Public Health, University of South Florida, Tampa, FL, USA.
Evgenios AgathokleousSchool of Ecology and Applied Meteorology, Nanjing University of Information Science & Technology, Nanjing, 210044, China.
Gaurav DhawanSri Guru Ram Das (SGRD) University of Health Sciences Amritsar, India, Hartford, CT, United States.
Rachna KapoorSaint Francis Hospital and Medical Center, Hartford, CT, USA.
Japjee ParmarGovernment Medical College, Amritsar, India.
Ibrahim MssillouNational Agency of Medicinal and Aromatic Plants, BP 159, Principal, 34000, Taounate, Morocco.
Vittorio CalabreseDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia 97, 95123, Catania, Italy.

Funding

ExxonMobil Foundation S18200000000256US Air Force AFOSR FA9550-19-1-0413
6 · The paper itself

Abstract

The present paper provides the first integrated assessment of the capacity of the flavonol, fisetin, to induce hormetic dose responses. Fisetin was shown to induce hormetic dose responses in cellular and in vivo animal model systems affecting a broad range of endpoints of potential therapeutic and public health significance across the entire lifespan. Fisetin was effective in slowing aging processes, acting as a senolytic agent in multiple organ systems, in an hormetic fashion. In addition, fisetin was broadly neuroprotective, including during fetal development, and preventing the toxicity of methylmercury. Since these findings indicate that fisetin may have the potential to induce multi-system chemoprotective effects, it indicates the need to better clarify the absorption and bioavailability of fisetin and ways to enhance its efficiency.

Indexed as

AgingFlavonoidsHormesisNeuroprotective AgentsSenotherapeuticsAnimalsDose-Response Relationship, DrugFlavonolsHumansfisetinFlavonoidsFlavonolsNeuroprotective AgentsSenotherapeuticsAdaptogenBiphasic dose responseChemoprotectionHormesisHormetinLifespanSupplements

Identifiers

PMID40208387

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.